Movetis advised by Eubelius in respect of public tender offer by Shire
03/08/2010Movetis NV, the European specialty pharmaceutical company focused on the discovery, development and commercialisation of drugs for the treatment of diseases in the GI area, on 3 August 2010 received a conditional offer from a Luxembourg wholly-owned subsidiary of Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, to acquire all outstanding shares and warrants of Movetis NV at an offer price of EUR 19.00 in cash per share, valuing the Company’s equity, on a fully diluted basis, at EUR 428 million.
The shares of Movetis are admitted to trading on Euronext Brussels.
The Eubelius team advising Movetis in respect of the public tender offer by Shire is led by Lars Van Bever and Matthias Wauters.
All news
